Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 28, 2014; 20(44): 16389-16397
Published online Nov 28, 2014. doi: 10.3748/wjg.v20.i44.16389
Published online Nov 28, 2014. doi: 10.3748/wjg.v20.i44.16389
Ulcerative colitis-associated colorectal cancer
Masakazu Yashiro, Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan
Masakazu Yashiro, Oncology Institute of Geriatrics and Medical Science, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan
Author contributions: Yashiro M solely contributed to the manuscript.
Correspondence to: Masakazu Yashiro, MD, PhD, Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. m9312510@med.osaka-cu.ac.jp
Telephone: +81-6-66453838 Fax: +81-6-66466450
Received: May 27, 2014
Revised: September 15, 2014
Accepted: October 14, 2014
Published online: November 28, 2014
Processing time: 188 Days and 16.6 Hours
Revised: September 15, 2014
Accepted: October 14, 2014
Published online: November 28, 2014
Processing time: 188 Days and 16.6 Hours
Core Tip
Core tip: Colorectal cancer (CRC) is more frequent in patients with long-term ulcerative colitis (UC), and is one of the most serious and life threatening consequences of UC. Knowledge of risk factors for CRC is important to identify UC patients who need surveillance. Colonoscopy surveillance programs are recommended to reduce the risk of CRC and mortality in UC. Genetic alterations might play a role in the development of CRC in UC patients. 5-aminosalicylates might represent a favorable therapeutic option for chemoprevention of CRC.